At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,480 enrolled
Drug / intervention
EkoSonic Endovascular System with thrombolyticdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Retrospective and Prospective International EkoSonic® Registry of the Treatment and Clinical OUTcomes of Patients With Pulmonary Embolism
In Brief
An observational study evaluating EkoSonic Endovascular System with thrombolytic for Pulmonary Embolism and Thrombosis. Completed, enrolled 1,480 participants across 80 sites in 8 countries.
Detailed Summary
This registry is designed to understand acoustic pulse thrombolysis (APT) treatment regimens used as standard of care globally for pulmonary embolism. The registry will include individuals who have already received the APT treatment and those that will undergo APT treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Embolism and Thrombosis
CountriesAustria, France, Germany, Netherlands, Switzerland, Turkey (Türkiye), United Kingdom, United States
CollaboratorsBTG International Inc.
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMar 2018
Primary CompletionJun 2020
Study CompletionSep 2020
TodayJul 2026
First PostedFeb 8, 2018
Enrollment StartMar 1, 2018
Primary CompletionJun 30, 2020
Study CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.4 years ago
Interventions
EkoSonic Endovascular System with thrombolyticdevice
The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.